On February 21, 2025, a delegation from Muyuan Group, a leading Chinese agribusiness conglomerate, visited Fangtong for a comprehensive research and strategic dialogue. The delegation, comprising senior executives and technical experts, was warmly received by Liu Lixia, Vice General Manager of Fangtong Animal Pharmaceuticals, alongside Fangtong’s leadership team.
Founded in 1992, Muyuan Group has evolved into a diversified modern enterprise spanning feed processing, breeding stock selection, hog farming, and meat processing. In 2024, the group achieved a milestone with live hog production surpassing 71.6 million head, solidifying its position as a benchmark for private enterprises in China’s agricultural sector. Fangtong, a leading veterinary pharmaceutical manufacturer, has maintained a strategic partnership with Muyuan Group since 2004. Despite market challenges in the past year, the two companies demonstrated resilience through mutual trust and collaboration, delivering commendable performance in 2024.
During the symposium, the delegation expressed gratitude for Fangtong’s long-standing support, highlighting the purpose of their visit: conducting on-site inspections of production processes and packaging formats, and engaging in in-depth discussions on biosecurity measures and technical service enhancements. At the same time, Muyuan’s procurement team reviewed collaborative achievements in 2024, expressing appreciation for Fangtong’s role as a core partner in delivering high-quality veterinary products and technical expertise. Plans for deepened collaboration in 2025 were outlined, with a focus on addressing emerging challenges in livestock health through innovation and knowledge-sharing.
In response to Muyuan’s feedback, Vice General Manager Liu Lixia pledged to leverage the Fangtong’s expertise in veterinary pharmaceuticals to optimize product portfolios, enhance quality control, and streamline clinical applications. Fangtong further committed to advancing joint R&D initiatives with Muyuan, including experimental data analysis for core products, new drug development, and regulatory submissions for veterinary medicines. “We aim to forge a new chapter in our strategic alliance, driving sustainable growth for both parties,” Liu emphasized.
Following the discussions, the delegation visited Fangtong’s production facilities, gaining in-depth insights into Fangtong’s production scale, rigorous quality control capabilities, and logistics infrastructure. The delegation was deeply impressed by Fangtong’s advanced production processes, stringent quality management system, and efficient logistics and distribution system, which further strengthened mutual confidence in cooperation. They highly praised Fangtong’s professional management and standardized operations, as well as its comprehensive strength in product research and development, quality testing, GMP management, and laboratory equipment.
This exchange visit not only deepened mutual understanding but also laid a solid foundation for further cooperation in the future. Fangtong appreciates the recognition from the leadership and experts of Muyuan Group. With over twenty years of experience, Fangtong remains focused on the research, production, and service of animal medicines. Fangtong looks forward to further strengthening its collaboration with Muyuan Group, promoting high-quality development, and contributing to the advancement of livestock farming industry.
Send your message to us:
Post time: Feb-25-2025